4-chloromethyl-5-phenyl-1,3-dioxolen-2-one | 80841-80-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloromethyl-5-phenyl-1,3-dioxolen-2-one
• 英文别名: 4-(Chloromethyl)-5-phenyl-1,3-dioxol-2-one
• CAS: 80841-80-1
• 化学式: C₁₀H₇ClO₃
• 分子量: 210.617
• InChiKey: NFPVRVVXCABZIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloromethyl-5-phenyl-1,3-dioxolen-2-one 在 四丁基溴化铵 、 sodium iodide 、 calcium chloride 作用下， 以 乙酸乙酯 为溶剂， 生成 4-iodomethyl-2-oxo-5-phenyl-1,3-dioxolene
  参考文献：
  名称：

  CN114478494

  摘要：

  公开号：

文献信息

• Studies on prodrugs. III. A convenient and practical preparation of ampicillin prodrugs.
  作者：SHOJI IKEDA、FUMIO SAKAMOTO、HIROSATO KONDO、MASARU MORIYAMA、GORO TSUKAMOTO

  DOI：10.1248/cpb.32.4316

  日期：——

  In order to prepare ampicillin prodrugs conveniently for practical use, a new synthetic method for 6β-aminopenicillanic acid (6-APA) esters as key intermediates of various ampicillin prodrugs has been developed. Acylation of 6-APA esters to ampicillin esters was achieved in good yields by using phenylglycyl chloride hydrochloride in dichloromethane in the presence of sodium bicarbonate and amide, or ammonium bicarbonate alone. KBT-1585, bacampicillin, talampicillin and pivampicillin have been obtained in good yields by this procedure.

  为了便于制备实用的氨苄西林前药，开发了一种新的合成方法，用于作为各种氨苄西林前药关键中间体的6β-氨苄青霉烷酸（6-APA）酯。通过在二氯甲烷中使用苯基甘氨酰氯盐酸盐，并在碳酸氢钠和酰胺或单独使用碳酸氢铵的存在下进行酰化反应，成功地将6-APA酯转化为氨苄西林酯，产率良好。通过此方法，KBT-1585、巴氨西林、他拉西林和匹氨西林均以良好产率获得。
• Strain of streptomyces
  申请人：SANKYO COMPANY LIMITED

  公开号：US20030069204A1

  公开（公告）日：2003-04-10

  The present invention relates to ester, ether and N-alkylcarbamoyl derivatives of compound (Ia) and pharmaceutically acceptable salts thereof. These compounds exhibit excellent antibacterial activity and are useful for the treatment or prevention of bacterial infections. 1 (wherein R 1 is a hydrogen atom or a methyl group; R 2 a is a hydrogen atom, a protecting group for a hydroxy group, or a methyl group; R 3 is a hydrogen atom or a protecting group for a hydroxy group; R 4 a is a hydrogen atom, a hydroxy group or a protected hydroxy group; R 5 is a hydrogen atom or a protecting group for a hydroxy group; and X is a methylene group or a sulfur atom). The invention also includes compounds which are related to the aforeidentified compounds.

  本发明涉及化合物（Ia）的酯、醚和N-烷基氨基甲酰衍生物及其药学上可接受的盐。这些化合物表现出优异的抗菌活性，并可用于治疗或预防细菌感染。其中，R1是氢原子或甲基基团；R2a是氢原子、羟基保护基或甲基基团；R3是氢原子或羟基保护基；R4a是氢原子、羟基或受保护的羟基；R5是氢原子或羟基保护基；X是亚甲基或硫原子。本发明还包括与上述化合物相关的化合物。
• 6-(1-Hydroxyethyl)-2-SR8-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters
  申请人：Merck & Co., Inc.

  公开号：EP0113101A1

  公开（公告）日：1984-07-11

  Diselosed are 6-[1-hydroxyethyl)-2-SR5-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters (I) which are oralfy active antibiotics: wherein: R is a pharmaceutically acceptable ester moiety consistent with oral delivery; and R' is substituted or unsubstituted: alkyl, alkenyl, alkynyl, or cyclic alkyl, alkenyl, alkynyl, having 1-6 carbon atoms, aryl such as phenyl or heteroaryl such as pyridyl; wherein the substituent or substituents are selected from: phenyl, pyridyl, cyano, fluoro, chloro, hydroxy, alkylthio such as methylthio, arylthio such as phenylthio, methoxy, phenoxy, alkoxycarbonyl such as methoxycarbonyl, acetoxyl, N-methylcarbamoyl, N-methylcarbamoyloxy and N-acylamino. Also disclosed are processes for the preparation of such compounds and pharmaceutical compositions comprising such compounds.

  分离出的 6-[1-羟乙基]-2-SR5-1-甲基-1-巴豆硫杂庚烯-2-em-3-羧酸酯 (I) 是一种具有或半活性的抗生素： 其中R是符合口服给药的药学上可接受的酯基；R'是取代或未取代的：烷基、烯基、炔基，或具有 1-6 个碳原子的环状烷基、烯基、炔基，芳基如苯基或杂芳基如吡啶基；其中的取代基或多个取代基选自：苯基、吡啶基、氰基、氟基、氯基、羟基、烷硫基如甲硫基、芳硫基如苯硫基、甲氧基、苯氧基、烷氧基羰基如甲氧基羰基、乙酰氧基、N-甲基氨基甲酰基、N-甲基氨基甲酰氧基和 N-酰氨基。 还公开了制备此类化合物的工艺和包含此类化合物的药物组合物。
• NOVEL ANTIBACTERIAL COMPOUNDS
  申请人：Sankyo Company Limited

  公开号：EP1095947A1

  公开（公告）日：2001-05-02

  The present invention relates to ester, ether and N-alkylcarbamoyl derivatives of compound (Ia) and pharmaceutically acceptable salts thereof. These compounds exhibit excellent antibacterial activity and are useful for the treatment or prevention of bacterial infections. (wherein R1 is a hydrogen atom or a methyl group; R2a is a hydrogen atom, a protecting group for a hydroxy group, or a methyl group; R3 is a hydrogen atom or a protecting group for a hydroxy group; R4a is a hydrogen atom, a hydroxy group or a protected hydroxy group; R5 is a hydrogen atom or a protecting group for a hydroxy group; and X is a methylene group or a sulfur atom).

  本发明涉及化合物（Ia）的酯类、醚类和 N-烷基氨基甲酰基衍生物及其药学上可接受的盐类。这些化合物具有优异的抗菌活性，可用于治疗或预防细菌感染。 (其中 R1 是氢原子或甲基；R2a 是氢原子、羟基保护基团或甲基；R3 是氢原子或羟基保护基团；R4a 是氢原子、羟基或羟基保护基团；R5 是氢原子或羟基保护基团；X 是亚甲基或硫原子）。
• Novel antibacterial compounds
  申请人：Sankyo Company, Limited

  公开号：EP1319406A1

  公开（公告）日：2003-06-18

  The use of compounds of formula (I), defined herein, or pharmaceutically acceptable salts thereof, or of pharmaceutically acceptable esters, ethers or N-alkylcarbamoyl derivatives of compounds of formula (Ia), defined herein, or phamaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prevention of a bacterial infection caused by Mycobacterium bacteria is disclosed. The invention further provides the use of capuramycin in the manufacture of a medicament for the treatment or prevention of a bacterial infection caused by Mycobacterium tuberculosis bacteria.

  本发明公开了本文定义的式(I)化合物或其药学上可接受的盐，或本文定义的式(Ia)化合物或其药学上可接受的盐的药学上可接受的酯、醚或N-烷基氨基甲酰基衍生物在制造治疗或预防由分枝杆菌引起的细菌感染的药物中的用途。本发明进一步提供了卡曲霉素在制造治疗或预防结核分枝杆菌引起的细菌感染的药物中的用途。